All Hong Kong stocks quotes are at least 15 minutes delayed.
02367
GIANT BIOGENE
HKD
36.2800.240
(0.67%)
1D
High
38.000
Open
37.620
VWAP
36.83
Vol
6.27M
Mkt Cap
40.57B
Low
36.100
Amount
231.06M
EV/EBITDA(TTM)
10.00
Total Shares
1.07B
EV
3.72B
EV/OCF(TTM)
13.59
P/S(TTM)
5.53
Giant Biogene Holding Co Ltd is an investment holding company primarily engaged in the research, development, manufacture and sale of bioactive material-based beauty and health products. The Company's main products include professional skin treatment products such as functional skincare products and medical dressings, as well as functional foods and others. The Company mainly conducts its businesses in domestic market.
Show More
News
4.0
2025-12-23aastocksCMSI Lowers GIANT BIOGENE Rating to Neutral and Reduces Target Price to HKD34.5
Investment Shift: GIANT BIOGENE's investment outlook has changed from growth to strategic adjustment due to a public relations crisis, with an anticipated adjustment period starting in 2026.
Profit Forecast Downgrade: CMSI has reduced its net profit forecast for GIANT BIOGENE by over 30% on average, now predicting a 12% lower profit than market expectations.
Rating Change: The company's rating has been downgraded from Buy to Neutral, reflecting a significant decrease in confidence.
Target Price Reduction: M Stanley has lowered GIANT BIOGENE's target price from HKD64 to HKD34.5, anticipating increased marketing efforts to aid in sales recovery.
7.0
2025-12-17aastocksM Stanley Lowers GIANT BIOGENE (02367.HK) Price Target to $42, Anticipates Boost in Sales from Enhanced Marketing Efforts
Sales Guidance Adjustment: GIANT BIOGENE has revised its 2025 sales growth forecast from 25% to flat or a mild decline due to industry challenges, as reported by Morgan Stanley.
Marketing Strategy for Recovery: The company plans to increase marketing investments to counteract past controversies and support new product launches, which is expected to help rebuild brand momentum without significantly impacting profits.
Revenue Forecast Downgrade: Morgan Stanley has cut GIANT BIOGENE’s revenue projections for 2025-2027 by 20%, 32%, and 35%, respectively, predicting an 8% drop in net profit for 2025 and 2026, followed by a 20% rebound in 2027.
Target Price and Rating Change: UBS has downgraded GIANT BIOGENE to a Neutral rating and reduced its target price from HKD 78 to HKD 42, while Morgan Stanley maintains an Overweight rating despite the lowered forecasts.
6.0
2025-12-11aastocksUBS Lowers GIANT BIOGENE (02367.HK) Rating to Neutral and Reduces Price Target to $39.5
UBS Downgrade: UBS downgraded GIANT BIOGENE (02367.HK) from Buy to Neutral due to increased uncertainty regarding short-term revenue and profit outlook, lowering its target price from $79.5 to $39.5.
Earnings Forecast Reduction: The broker reduced its earnings forecasts for 2025-2027 by 25-41% and revenue forecasts by 20-36%.
Market Competition: The report highlighted intensified market competition with emerging skincare brands offering more attractive pricing and using recombinant collagen as a core ingredient.
Product Innovation Uncertainty: Despite rapid product innovation by GIANT BIOGENE, there is uncertainty about the success of new products expected to launch next year.
4.0
2025-12-05aastocksHSBC Research Lowers GIANT BIOGENE's Target Price to HKD46.4, Maintains Buy Rating
Earnings Guidance Update: GIANT BIOGENE updated its full-year results guidance and highlighted risks to 2025 earnings during a conference call, with HSBC Global Research reporting a significant earnings forecast reduction of 17-25% for 2025-27 due to pressures on the Comfy brand.
Target Price Adjustment: CMBI has maintained a "Buy" rating for GIANT BIOGENE but lowered its target price from HKD 69.3 to HKD 46.4 in light of the revised earnings expectations.
8.0
2025-12-04aastocksCICC Lowers GIANT BIOGENE's Target Price to HKD56, Remains Positive on Medium- to Long-Term Growth Prospects
Share Repurchase Announcement: GIANT BIOGENE plans to repurchase up to 104 million shares, representing 10% of its issued shares, and aims to enhance its product matrix, brand operations, and channel development by 2026.
Management Confidence: CICC views the buyback as a sign of management's confidence, highlighting the company's strong R&D capabilities and brand recognition, which are expected to drive operational improvements and growth in the medical beauty sector.
Target Price Adjustment: BofAS has reduced GIANT BIOGENE's target price by 20% to HKD56 while maintaining an Outperform rating, indicating a cautious outlook despite the company's potential.
Short Selling Data: The company has reported short selling of $87.94 million, with a ratio of 16.967%, reflecting market sentiment and trading activity surrounding its stock.
Money Flow
Over the past 66 trading days, overall net money flow is 57.57M, with retail investors contributing 1.91M and major investors adding 28.81M.
Net Buy $ Volume
Net Sell $ Volume
CMSI
CMSI
Buy
to
Neutral
downgrade
$64
2025-12-23
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was downgraded from Buy to Neutral due to a public relations crisis that has shifted the investment logic from growth to strategic adjustment. The company is expected to enter an adjustment period in 2026 without any catalysts, and CMSI has revised its net profit forecast for GIANT BIOGENE to be 12% lower than market expectations, cutting the forecast by over 30% on average. Additionally, the target price was reduced from HKD 64 to HKD 34.5.
CMSI
Buy
to
Neutral
Price Target
$64
2025-12-23
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) was downgraded from Buy to Neutral due to a public relations crisis that has shifted the investment logic from growth to strategic adjustment. The company is expected to enter an adjustment period in 2026 without any catalysts, and CMSI has revised its net profit forecast for GIANT BIOGENE to be 12% lower than market expectations, cutting the forecast by over 30% on average. Additionally, the target price was reduced from HKD 64 to HKD 34.5.
Morgan Stanley
Morgan Stanley
Overweight
to
Neutral
downgrade
$78 -> $42
2025-12-17
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was adjusted to "Neutral" by UBS, with a target price slashed to $39.5, primarily due to a significant downward revision in the company's sales guidance and revenue forecasts. Morgan Stanley's report indicated that the company adjusted its 2025 sales growth expectation from 25% to flat or a mild decline, influenced by industry headwinds that hindered previously projected growth during key periods. Additionally, Morgan Stanley revised its revenue forecasts for 2025-27 down by 20%, 32%, and 35%, respectively, and anticipated a net profit drop of 8% year-over-year in 2025 and 2026, although a rebound of 20% was expected in 2027. The overall sentiment reflects concerns about the company's ability to achieve its growth targets amidst these challenges.
Morgan Stanley
Overweight
to
Neutral
Price Target
$78 -> $42
2025-12-17
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) was adjusted to "Neutral" by UBS, with a target price slashed to $39.5, primarily due to a significant downward revision in the company's sales guidance and revenue forecasts. Morgan Stanley's report indicated that the company adjusted its 2025 sales growth expectation from 25% to flat or a mild decline, influenced by industry headwinds that hindered previously projected growth during key periods. Additionally, Morgan Stanley revised its revenue forecasts for 2025-27 down by 20%, 32%, and 35%, respectively, and anticipated a net profit drop of 8% year-over-year in 2025 and 2026, although a rebound of 20% was expected in 2027. The overall sentiment reflects concerns about the company's ability to achieve its growth targets amidst these challenges.
UBS
UBS
Buy
to
Neutral
downgrade
2025-12-11
Reason
The analyst rating downgrade from Buy to Neutral for GIANT BIOGENE (02367.HK) by UBS is primarily due to increased uncertainty over the company's short-term revenue and profit outlook. UBS has also lowered its earnings forecasts for 2025-2027 by 25-41% and reduced revenue forecasts for the same period by 20-36%. Additionally, the report highlights intensified market competition from other skincare brands offering more attractive pricing and using similar core ingredients, which adds to the uncertainty regarding the success of GIANT BIOGENE's new products in the upcoming year.
UBS
Buy
to
Neutral
Price Target
2025-12-11
downgrade
The analyst rating downgrade from Buy to Neutral for GIANT BIOGENE (02367.HK) by UBS is primarily due to increased uncertainty over the company's short-term revenue and profit outlook. UBS has also lowered its earnings forecasts for 2025-2027 by 25-41% and reduced revenue forecasts for the same period by 20-36%. Additionally, the report highlights intensified market competition from other skincare brands offering more attractive pricing and using similar core ingredients, which adds to the uncertainty regarding the success of GIANT BIOGENE's new products in the upcoming year.
Bank of America Securities
BofAS
Buy
downgrade
2025-12-05
Reason
The analyst rating for GIANT BIOGENE (02367.HK) was kept as "Buy" despite a reduction in the target price from HKD 69.3 to HKD 46.4. This decision was influenced by the downward revision of earnings expectations due to growth pressures on the Comfy brand, which led to a 17-25% decrease in the 2025-27 earnings forecasts. However, the potential positive impact of the medical beauty business in 2026 was noted as a catalyst that could support the company's performance.
Bank of America Securities
Buy
Price Target
2025-12-05
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) was kept as "Buy" despite a reduction in the target price from HKD 69.3 to HKD 46.4. This decision was influenced by the downward revision of earnings expectations due to growth pressures on the Comfy brand, which led to a 17-25% decrease in the 2025-27 earnings forecasts. However, the potential positive impact of the medical beauty business in 2026 was noted as a catalyst that could support the company's performance.
CMB International
CMB International
Buy
downgrade
$53.89
2025-12-04
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is maintained as a "Buy" despite short-term sales pressure during the Double 11 period. This decision is based on the company's strategic adjustments, including a focus on preserving price levels and consumer experience, as well as increasing the proportion of self-broadcast channels. These actions are seen as laying a foundation for long-term growth. However, the revenue growth rate for 2025 and 2026 has been revised downward due to the sales miss, leading to a target price adjustment to HKD53.89.
CMB International
Buy
Price Target
$53.89
2025-12-04
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) is maintained as a "Buy" despite short-term sales pressure during the Double 11 period. This decision is based on the company's strategic adjustments, including a focus on preserving price levels and consumer experience, as well as increasing the proportion of self-broadcast channels. These actions are seen as laying a foundation for long-term growth. However, the revenue growth rate for 2025 and 2026 has been revised downward due to the sales miss, leading to a target price adjustment to HKD53.89.
BofAS
BofAS
Outperform
to
Buy
downgrade
$70 -> $56
2025-12-04
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is positive due to several key factors highlighted in the article. CICC views the company's plan to repurchase up to 104 million shares as a demonstration of management's confidence in the business. They believe that GIANT BIOGENE's strong R&D capabilities, brand recognition, and team cohesion will enable the company to enhance its operations by optimizing its product structure and adjusting operational strategies effectively. Additionally, the anticipated growth in its second curve medical beauty business contributes to CICC's optimistic outlook on the company's medium- to long-term growth potential, positioning it as a leader in recombinant collagen.
BofAS
Outperform
to
Buy
Price Target
$70 -> $56
2025-12-04
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) is positive due to several key factors highlighted in the article. CICC views the company's plan to repurchase up to 104 million shares as a demonstration of management's confidence in the business. They believe that GIANT BIOGENE's strong R&D capabilities, brand recognition, and team cohesion will enable the company to enhance its operations by optimizing its product structure and adjusting operational strategies effectively. Additionally, the anticipated growth in its second curve medical beauty business contributes to CICC's optimistic outlook on the company's medium- to long-term growth potential, positioning it as a leader in recombinant collagen.
CICC
CICC
Outperform
to
Buy
downgrade
$70 -> $56
2025-12-03
Reason
The analyst rating from CICC for GIANT BIOGENE (02367.HK) is based on several positive factors. They view the company's plan to repurchase up to 104 million shares as a sign of management's confidence. Additionally, CICC highlights the company's solid research and development capabilities, strong brand recognition, and team cohesion. They believe that GIANT BIOGENE can enhance its operations through product structure optimization and strategic adjustments, particularly in its growing medical aesthetics business. CICC remains optimistic about the company's mid-to-long term growth potential as a leader in recombinant collagen, which supports their Outperform rating, despite a 20% cut in the target price to HKD56.
CICC
Outperform
to
Buy
Price Target
$70 -> $56
2025-12-03
downgrade
The analyst rating from CICC for GIANT BIOGENE (02367.HK) is based on several positive factors. They view the company's plan to repurchase up to 104 million shares as a sign of management's confidence. Additionally, CICC highlights the company's solid research and development capabilities, strong brand recognition, and team cohesion. They believe that GIANT BIOGENE can enhance its operations through product structure optimization and strategic adjustments, particularly in its growing medical aesthetics business. CICC remains optimistic about the company's mid-to-long term growth potential as a leader in recombinant collagen, which supports their Outperform rating, despite a 20% cut in the target price to HKD56.
BofA Securities
BofA Securities
Buy
downgrade
2025-12-03
Reason
The analyst rating from BofA Securities for GIANT BIOGENE is maintained at "Buy" despite lowering revenue and net profit forecasts for 2025-2027. The reason for this rating is the expectation that a newly approved injectable medical aesthetics product will serve as a new growth driver for the company in the upcoming year.
BofA Securities
Buy
Price Target
2025-12-03
downgrade
The analyst rating from BofA Securities for GIANT BIOGENE is maintained at "Buy" despite lowering revenue and net profit forecasts for 2025-2027. The reason for this rating is the expectation that a newly approved injectable medical aesthetics product will serve as a new growth driver for the company in the upcoming year.
Citi
Buy
downgrade
2025-12-03
Reason
The analyst rating for GIANT BIOGENE (02367.HK) is a "Buy" based on the expectation of a return to double-digit growth next year, driven by the continued growth of its live-streaming business and the launch of several major new products. However, the rating comes with a cautionary note, as the company's latest results guidance is at the lower end of market expectations, prompting Citi to cut its target price from HKD55.4 to HKD44.6.
Citi
Buy
Price Target
2025-12-03
downgrade
The analyst rating for GIANT BIOGENE (02367.HK) is a "Buy" based on the expectation of a return to double-digit growth next year, driven by the continued growth of its live-streaming business and the launch of several major new products. However, the rating comes with a cautionary note, as the company's latest results guidance is at the lower end of market expectations, prompting Citi to cut its target price from HKD55.4 to HKD44.6.
CMBI
CMBI
Buy
downgrade
2025-10-24
Reason
The analyst rating for GIANT BIOGENE remains a "Buy" despite a reduction in the target price from HKD71.3 to HKD58.35. This decision is based on the company's recent approval of its first injectable recombinant collagen product, which signifies a significant advancement in its product offerings and the completion of a comprehensive product matrix in the medical aesthetic sector. The ongoing commercialization of its injectable products further supports the positive outlook, leading the analyst to maintain the Buy rating.
CMBI
Buy
Price Target
2025-10-24
downgrade
The analyst rating for GIANT BIOGENE remains a "Buy" despite a reduction in the target price from HKD71.3 to HKD58.35. This decision is based on the company's recent approval of its first injectable recombinant collagen product, which signifies a significant advancement in its product offerings and the completion of a comprehensive product matrix in the medical aesthetic sector. The ongoing commercialization of its injectable products further supports the positive outlook, leading the analyst to maintain the Buy rating.
Valuation Metrics
Forward PE
5Y Average PE
21.37
Current PE
13.42
Overvalued PE
26.23
Undervalued PE
16.51
Forward EV/EBITDA
5Y Average EV/EBITDA
16.20
Current EV/EBITDA
8.90
Overvalued EV/EBITDA
20.57
Undervalued EV/EBITDA
11.82
Forward PS
5Y Average PS
8.24
Current PS
4.79
Overvalued PS
10.35
Undervalued PS
6.13
Financials
Al Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
Buyback
Short Selling
People Also Watch